LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

Search

Bio-Techne Corp

Закрыт

СекторЗдравоохранение

57.69 4.97

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

56.94

Макс.

58.08

Ключевые показатели

By Trading Economics

Доход

13M

51M

Продажи

16M

311M

P/E

Средняя по отрасли

80.243

49.712

Прибыль на акцию

0.53

Дивидендная доходность

0.59

Рентабельность продаж

16.392

Сотрудники

3,100

EBITDA

21M

99M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+3.37% upside

Дивиденды

By Acuity

Дивидендная доходность

Средняя по отрасли

0.59%

2.36%

Следующий отчет о доходах

5 авг. 2026 г.

Дата следующей выплаты дивидендов

28 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

230M

8.8B

Предыдущая цена открытия

52.72

Предыдущая цена закрытия

57.69

Новостные настроения

By Acuity

76%

24%

302 / 342 Рейтинг в Healthcare

Bio-Techne Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

О компании Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat